![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MDM2 |
Gene summary for MDM2 |
![]() |
Gene information | Species | Human | Gene symbol | MDM2 | Gene ID | 4193 |
Gene name | MDM2 proto-oncogene | |
Gene Alias | ACTFS | |
Cytomap | 12q15 | |
Gene Type | protein-coding | GO ID | GO:0000075 | UniProtAcc | A0A0A8KB75 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
4193 | MDM2 | GSM4909291 | Human | Breast | IDC | 4.00e-35 | 1.02e+00 | 0.1753 |
4193 | MDM2 | GSM4909298 | Human | Breast | IDC | 1.99e-02 | 1.18e-01 | 0.1551 |
4193 | MDM2 | GSM4909319 | Human | Breast | IDC | 2.18e-03 | -9.07e-02 | 0.1563 |
4193 | MDM2 | GSM4909321 | Human | Breast | IDC | 7.69e-05 | 2.95e-01 | 0.1559 |
4193 | MDM2 | NCCBC2 | Human | Breast | DCIS | 1.34e-04 | 5.66e-01 | 0.1554 |
4193 | MDM2 | P3 | Human | Breast | IDC | 6.07e-08 | 8.21e-01 | 0.1542 |
4193 | MDM2 | DCIS2 | Human | Breast | DCIS | 3.34e-39 | 1.77e-01 | 0.0085 |
4193 | MDM2 | LZE4T | Human | Esophagus | ESCC | 1.15e-22 | 5.77e-01 | 0.0811 |
4193 | MDM2 | LZE7T | Human | Esophagus | ESCC | 3.46e-11 | 7.97e-01 | 0.0667 |
4193 | MDM2 | LZE8T | Human | Esophagus | ESCC | 3.13e-09 | 2.57e-01 | 0.067 |
4193 | MDM2 | LZE20T | Human | Esophagus | ESCC | 2.15e-04 | 1.80e-01 | 0.0662 |
4193 | MDM2 | LZE22D1 | Human | Esophagus | HGIN | 3.08e-03 | 2.49e-01 | 0.0595 |
4193 | MDM2 | LZE24T | Human | Esophagus | ESCC | 2.94e-15 | 5.07e-01 | 0.0596 |
4193 | MDM2 | LZE21T | Human | Esophagus | ESCC | 7.88e-03 | 4.10e-01 | 0.0655 |
4193 | MDM2 | LZE6T | Human | Esophagus | ESCC | 1.11e-02 | 2.06e-01 | 0.0845 |
4193 | MDM2 | P1T-E | Human | Esophagus | ESCC | 7.82e-08 | 5.82e-01 | 0.0875 |
4193 | MDM2 | P2T-E | Human | Esophagus | ESCC | 5.41e-56 | 1.09e+00 | 0.1177 |
4193 | MDM2 | P4T-E | Human | Esophagus | ESCC | 2.97e-18 | 4.90e-01 | 0.1323 |
4193 | MDM2 | P5T-E | Human | Esophagus | ESCC | 1.44e-16 | 3.41e-01 | 0.1327 |
4193 | MDM2 | P8T-E | Human | Esophagus | ESCC | 1.74e-21 | 4.87e-01 | 0.0889 |
Page: 1 2 3 4 5 6 7 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00903169 | Prostate | BPH | positive regulation of intracellular protein transport | 55/3107 | 160/18723 | 3.09e-08 | 8.91e-07 | 55 |
GO:004586118 | Prostate | BPH | negative regulation of proteolysis | 98/3107 | 351/18723 | 5.43e-08 | 1.49e-06 | 98 |
GO:00109759 | Prostate | BPH | regulation of neuron projection development | 118/3107 | 445/18723 | 5.85e-08 | 1.57e-06 | 118 |
GO:003166910 | Prostate | BPH | cellular response to nutrient levels | 67/3107 | 215/18723 | 8.51e-08 | 2.12e-06 | 67 |
GO:003243617 | Prostate | BPH | positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 36/3107 | 90/18723 | 1.02e-07 | 2.49e-06 | 36 |
GO:007147910 | Prostate | BPH | cellular response to ionizing radiation | 31/3107 | 72/18723 | 1.07e-07 | 2.59e-06 | 31 |
GO:190305210 | Prostate | BPH | positive regulation of proteolysis involved in cellular protein catabolic process | 47/3107 | 133/18723 | 1.18e-07 | 2.81e-06 | 47 |
GO:004682215 | Prostate | BPH | regulation of nucleocytoplasmic transport | 40/3107 | 106/18723 | 1.35e-07 | 3.20e-06 | 40 |
GO:00447727 | Prostate | BPH | mitotic cell cycle phase transition | 112/3107 | 424/18723 | 1.57e-07 | 3.58e-06 | 112 |
GO:004343417 | Prostate | BPH | response to peptide hormone | 109/3107 | 414/18723 | 2.73e-07 | 5.91e-06 | 109 |
GO:00713759 | Prostate | BPH | cellular response to peptide hormone stimulus | 82/3107 | 290/18723 | 3.65e-07 | 7.65e-06 | 82 |
GO:003166718 | Prostate | BPH | response to nutrient levels | 121/3107 | 474/18723 | 3.68e-07 | 7.70e-06 | 121 |
GO:003033016 | Prostate | BPH | DNA damage response, signal transduction by p53 class mediator | 30/3107 | 72/18723 | 4.09e-07 | 8.44e-06 | 30 |
GO:190180010 | Prostate | BPH | positive regulation of proteasomal protein catabolic process | 41/3107 | 114/18723 | 4.33e-07 | 8.84e-06 | 41 |
GO:007145315 | Prostate | BPH | cellular response to oxygen levels | 56/3107 | 177/18723 | 5.50e-07 | 1.09e-05 | 56 |
GO:007121410 | Prostate | BPH | cellular response to abiotic stimulus | 89/3107 | 331/18723 | 1.28e-06 | 2.23e-05 | 89 |
GO:010400410 | Prostate | BPH | cellular response to environmental stimulus | 89/3107 | 331/18723 | 1.28e-06 | 2.23e-05 | 89 |
GO:00073468 | Prostate | BPH | regulation of mitotic cell cycle | 115/3107 | 457/18723 | 1.52e-06 | 2.62e-05 | 115 |
GO:003629415 | Prostate | BPH | cellular response to decreased oxygen levels | 51/3107 | 161/18723 | 1.66e-06 | 2.79e-05 | 51 |
GO:004682410 | Prostate | BPH | positive regulation of nucleocytoplasmic transport | 26/3107 | 62/18723 | 2.06e-06 | 3.40e-05 | 26 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0516922 | Breast | IDC | Epstein-Barr virus infection | 45/867 | 202/8465 | 3.16e-07 | 6.05e-06 | 4.52e-06 | 45 |
hsa0421824 | Breast | IDC | Cellular senescence | 35/867 | 156/8465 | 5.49e-06 | 7.43e-05 | 5.56e-05 | 35 |
hsa0520523 | Breast | IDC | Proteoglycans in cancer | 42/867 | 205/8465 | 7.69e-06 | 9.99e-05 | 7.48e-05 | 42 |
hsa0513124 | Breast | IDC | Shigellosis | 47/867 | 247/8465 | 1.78e-05 | 2.00e-04 | 1.49e-04 | 47 |
hsa0516324 | Breast | IDC | Human cytomegalovirus infection | 39/867 | 225/8465 | 6.66e-04 | 5.41e-03 | 4.05e-03 | 39 |
hsa0491916 | Breast | IDC | Thyroid hormone signaling pathway | 23/867 | 121/8465 | 2.45e-03 | 1.69e-02 | 1.27e-02 | 23 |
hsa0520322 | Breast | IDC | Viral carcinogenesis | 34/867 | 204/8465 | 2.82e-03 | 1.86e-02 | 1.39e-02 | 34 |
hsa052147 | Breast | IDC | Glioma | 16/867 | 75/8465 | 3.30e-03 | 2.10e-02 | 1.57e-02 | 16 |
hsa0521921 | Breast | IDC | Bladder cancer | 10/867 | 41/8465 | 7.07e-03 | 3.54e-02 | 2.65e-02 | 10 |
hsa0522010 | Breast | IDC | Chronic myeloid leukemia | 15/867 | 76/8465 | 9.24e-03 | 4.37e-02 | 3.27e-02 | 15 |
hsa0516932 | Breast | IDC | Epstein-Barr virus infection | 45/867 | 202/8465 | 3.16e-07 | 6.05e-06 | 4.52e-06 | 45 |
hsa0421834 | Breast | IDC | Cellular senescence | 35/867 | 156/8465 | 5.49e-06 | 7.43e-05 | 5.56e-05 | 35 |
hsa0520533 | Breast | IDC | Proteoglycans in cancer | 42/867 | 205/8465 | 7.69e-06 | 9.99e-05 | 7.48e-05 | 42 |
hsa0513134 | Breast | IDC | Shigellosis | 47/867 | 247/8465 | 1.78e-05 | 2.00e-04 | 1.49e-04 | 47 |
hsa0516334 | Breast | IDC | Human cytomegalovirus infection | 39/867 | 225/8465 | 6.66e-04 | 5.41e-03 | 4.05e-03 | 39 |
hsa0491917 | Breast | IDC | Thyroid hormone signaling pathway | 23/867 | 121/8465 | 2.45e-03 | 1.69e-02 | 1.27e-02 | 23 |
hsa0520332 | Breast | IDC | Viral carcinogenesis | 34/867 | 204/8465 | 2.82e-03 | 1.86e-02 | 1.39e-02 | 34 |
hsa0521413 | Breast | IDC | Glioma | 16/867 | 75/8465 | 3.30e-03 | 2.10e-02 | 1.57e-02 | 16 |
hsa0521931 | Breast | IDC | Bladder cancer | 10/867 | 41/8465 | 7.07e-03 | 3.54e-02 | 2.65e-02 | 10 |
hsa0522013 | Breast | IDC | Chronic myeloid leukemia | 15/867 | 76/8465 | 9.24e-03 | 4.37e-02 | 3.27e-02 | 15 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MDM2 | SNV | Missense_Mutation | novel | c.892G>A | p.Glu298Lys | p.E298K | Q00987 | protein_coding | deleterious(0.01) | benign(0.295) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
MDM2 | SNV | Missense_Mutation | rs773519801 | c.994C>T | p.Arg332Cys | p.R332C | Q00987 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A0CL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
MDM2 | SNV | Missense_Mutation | c.4N>C | p.Val2Leu | p.V2L | Q00987 | protein_coding | tolerated_low_confidence(0.33) | benign(0.176) | TCGA-E2-A158-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | arimidex | SD | |
MDM2 | SNV | Missense_Mutation | c.271T>G | p.Leu91Val | p.L91V | Q00987 | protein_coding | tolerated(0.65) | benign(0.013) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
MDM2 | SNV | Missense_Mutation | c.1038N>C | p.Glu346Asp | p.E346D | Q00987 | protein_coding | tolerated(0.51) | benign(0) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
MDM2 | SNV | Missense_Mutation | c.1483N>C | p.Tyr495His | p.Y495H | Q00987 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
MDM2 | SNV | Missense_Mutation | c.630N>T | p.Glu210Asp | p.E210D | Q00987 | protein_coding | tolerated(0.3) | possibly_damaging(0.718) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
MDM2 | SNV | Missense_Mutation | c.1370N>C | p.Val457Ala | p.V457A | Q00987 | protein_coding | deleterious(0) | possibly_damaging(0.616) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
MDM2 | SNV | Missense_Mutation | rs549965230 | c.781N>A | p.Asp261Asn | p.D261N | Q00987 | protein_coding | tolerated(0.52) | possibly_damaging(0.726) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
MDM2 | SNV | Missense_Mutation | c.1027G>A | p.Asp343Asn | p.D343N | Q00987 | protein_coding | tolerated(0.12) | benign(0.07) | TCGA-CM-5861-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4193 | MDM2 | CLINICALLY ACTIONABLE, ENZYME, TUMOR SUPPRESSOR, DRUGGABLE GENOME | RG7388 | IDASANUTLIN | ||
4193 | MDM2 | CLINICALLY ACTIONABLE, ENZYME, TUMOR SUPPRESSOR, DRUGGABLE GENOME | PD-98059 | CHEMBL35482 | 15385570 | |
4193 | MDM2 | CLINICALLY ACTIONABLE, ENZYME, TUMOR SUPPRESSOR, DRUGGABLE GENOME | DNDI1417132 | CHEMBL1492017 | ||
4193 | MDM2 | CLINICALLY ACTIONABLE, ENZYME, TUMOR SUPPRESSOR, DRUGGABLE GENOME | Platinum compounds | 29662106 | ||
4193 | MDM2 | CLINICALLY ACTIONABLE, ENZYME, TUMOR SUPPRESSOR, DRUGGABLE GENOME | RO5045337 | RO-5045337 | ||
4193 | MDM2 | CLINICALLY ACTIONABLE, ENZYME, TUMOR SUPPRESSOR, DRUGGABLE GENOME | HELENALIN | HELENALIN | ||
4193 | MDM2 | CLINICALLY ACTIONABLE, ENZYME, TUMOR SUPPRESSOR, DRUGGABLE GENOME | TCDD | 15459018 | ||
4193 | MDM2 | CLINICALLY ACTIONABLE, ENZYME, TUMOR SUPPRESSOR, DRUGGABLE GENOME | ANTIANGIOGENIC | 17138942 | ||
4193 | MDM2 | CLINICALLY ACTIONABLE, ENZYME, TUMOR SUPPRESSOR, DRUGGABLE GENOME | APG-115 | |||
4193 | MDM2 | CLINICALLY ACTIONABLE, ENZYME, TUMOR SUPPRESSOR, DRUGGABLE GENOME | PEMBROLIZUMAB | PEMBROLIZUMAB | 28351930 |
Page: 1 2 3 |